Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emiltatug Ledadotin - Mersana Therapeutics

Next Previous
Drug Profile

Emiltatug Ledadotin - Mersana Therapeutics

Alternative Names: B7-H4 ADC - Mersana Therapeutics; B7-H4 targeting antibody drug conjugate - Mersana Therapeutics; DAY-501; Emi-Le; XMT-1660

Latest Information Update: 17 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mersana Therapeutics
  • Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Adenoid cystic carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer

Most Recent Events

  • 31 Jan 2026 Day One Biopharmaceuticals has several patent pending applications for emiltatug ledadotin prior to January 2026
  • 31 Jan 2026 Day One Biopharmaceuticals owns patents for emiltatug ledadotin covering related components, intermediates, methods of manufacture, methods of treatment and nd methods of synthesising the payload in USA and other countries before January 2026
  • 06 Jan 2026 Mersana Therapeutics has been acquired by Day One Biopharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top